Every Peptide Term, Defined Properly

also: area under the curve, total exposure

The integrated total exposure of the body to a peptide over time, calculated as the area under the concentration-time curve.

also: F, systemic availability

The fraction of an administered peptide dose that reaches systemic circulation in an active, unmetabolized form.

also: CL, systemic clearance

The volume of plasma cleared of a peptide per unit time, typically by renal filtration, hepatic metabolism, or proteolytic degradation.

also: peak concentration, maximum plasma concentration

The maximum plasma concentration reached after a single dose of a peptide.

also: trough concentration, minimum plasma concentration

The lowest plasma concentration of a peptide during a dosing interval, typically measured immediately before the next dose.

also: t½, elimination half-life

The time required for the concentration of a peptide in the body to fall to half of its peak value.

also: steady-state concentration, Css

The point at which the rate of peptide administration equals the rate of elimination, producing a stable average plasma concentration.

also: SC absorption, SubQ uptake rate

The speed at which a peptide injected into subcutaneous tissue reaches systemic circulation.

also: tissue persistence, depot effect

The duration a peptide remains active within a specific tissue after plasma concentrations have fallen.

also: Vd, apparent volume of distribution

A theoretical volume describing how extensively a peptide distributes from plasma into tissues.

also: neovascularization, new blood vessel formation

The formation of new blood vessels from existing vasculature, critical for tissue repair, wound healing, and organ growth.

also: immune modulation, cytokine balancing

The alteration of cytokine signaling patterns, typically shifting the balance between pro-inflammatory and anti-inflammatory mediators.

also: GHRH mimetic, growth hormone releasing hormone analog

A synthetic peptide that mimics endogenous growth hormone releasing hormone at the GHRH receptor on pituitary somatotrophs.

also: GIPR, gastric inhibitory polypeptide receptor

A G-protein coupled receptor activated by glucose-dependent insulinotropic polypeptide, expressed in adipose tissue, pancreatic beta cells, and brain.

also: GLP-1R, glucagon-like peptide-1 receptor

A G-protein coupled receptor activated by glucagon-like peptide-1, expressed primarily in pancreatic beta cells, the central nervous system, and gastrointestinal tract.

also: GHS, GH secretagogue

A compound that triggers endogenous growth hormone release from the pituitary, typically by activating the ghrelin/GHS-R1a receptor.

also: mito biogenesis

The process by which cells generate new mitochondria, expanding cellular energy production capacity.

also: agonist

A molecule that binds to a receptor and triggers the same biological response as the endogenous ligand.

also: antagonist, receptor blocker

A molecule that binds to a receptor without activating it, preventing the endogenous ligand from triggering a response.

also: TA, telomere lengthening

The upregulation of telomerase enzyme activity, which extends or maintains telomere length at the ends of chromosomes.

also: lot-to-lot variability, batch consistency

The observed variability in purity, potency, or mass accuracy between different production lots of the same peptide from the same vendor.

also: certificate of analysis, lab report

A third-party laboratory report documenting the purity, identity, and mass of a peptide batch.

also: temperature-controlled shipping, refrigerated logistics

The unbroken maintenance of refrigerated temperatures during peptide storage, shipping, and handling.

also: HPLC, liquid chromatography

An analytical technique that separates, identifies, and quantifies compounds in a sample based on differential affinity with a chromatographic column.

also: freeze-drying, lyo

The process of freeze-drying a peptide to produce a stable, water-free solid powder for long-term storage.

also: MS, mass spec

An analytical technique that ionizes a compound and measures the mass-to-charge ratio of its fragments to confirm molecular identity.

also: RUO, for research use only

A regulatory designation indicating a compound is sold for laboratory research purposes and has not been evaluated for human use.

also: vendor rating, vendor reliability score

A composite metric evaluating peptide vendor reliability based on COA verification, batch consistency, shipping quality, and community feedback.

also: bacteriostatic water, bacteriostatic water for injection

Sterile water containing 0.9% benzyl alcohol, used to reconstitute lyophilized peptides for multi-dose vial use.

also: concentration, peptide concentration

The amount of peptide mass per unit volume of reconstituted solution, typically expressed as micrograms (mcg) or milligrams (mg) per milliliter.

also: drawing up, loading syringe

The technique of extracting a measured dose of reconstituted peptide from the vial into an insulin syringe.

also: site rotation, rotating sites

The practice of varying injection location across sessions to prevent tissue irritation, lipohypertrophy, and absorption inconsistency.

also: U-100 syringe, insulin pin

A small-gauge, low-volume syringe (typically 29–31 gauge, 0.3–1mL capacity) calibrated in insulin units for subcutaneous injection.

also: IM, intramuscular injection

Injection directly into muscle tissue, typically using a longer needle than subcutaneous injection.

also: recon, mixing

The process of dissolving a lyophilized peptide powder in bacteriostatic water or saline to produce an injectable solution.

also: SubQ, SC injection

Injection into the fatty layer immediately beneath the skin and above muscle tissue.

also: IU, syringe units

The volumetric graduations on a U-100 insulin syringe, where 100 units equals 1mL of solution.

also: shelf life, vial expiration

The duration a peptide remains stable and potent in its current physical state (lyophilized or reconstituted).

also: bro-science, forum report

An uncontrolled, self-reported account of individual experience with a compound, without systematic data collection or control conditions.

also: clinical study, human trial

A prospective research study testing a compound in human subjects under controlled protocol, typically organized into Phase 1 through Phase 4.

also: mechanism-of-action study, pathway study

Research investigating the molecular and cellular pathways through which a compound produces its effects.

also: N-of-1, single-subject study

A self-experiment in which an individual researcher systematically tests a protocol on themselves with structured data collection.

also: clinician protocols, expert protocol corpus

A curated knowledge base of clinician-validated peptide protocols, bloodwork reviews, and cycle audits sourced from practicing medical professionals.

also: animal study, in vivo / in vitro research

Research conducted in cell cultures (in vitro) or animal models (in vivo) prior to any human testing.

also: RCT, randomized controlled trial

A clinical trial design in which participants are randomly assigned to intervention or control groups, considered the gold-standard for causal inference.

also: three-lane framework, evidence tiers

DoseCraft's framework categorizing every compound across three independent evidence dimensions: Clinical, Expert, and Experimental.

also: protocol cycle, run

A defined period of peptide administration followed by a planned pause, structured to manage receptor sensitivity and measure effects.

also: loading dose, saturation phase

The initial period of a protocol during which elevated or frequent dosing rapidly builds tissue exposure to a target level.

also: maintenance, steady-state dose

The ongoing dose used to sustain target tissue exposure after any loading or titration phase is complete.

also: washout period, rest phase

The pause phase of a peptide cycle during which no compound is administered, allowing receptor recovery and isolated outcome measurement.

also: during cycle, active cycle

The active phase of a peptide cycle during which the compound is being administered.

also: tachyphylaxis, receptor downregulation

The reduction in receptor responsiveness over time due to sustained or high-dose agonist exposure.

also: protocol stack, peptide stack

A combination of two or more peptides used concurrently to produce additive or synergistic effects on a research target.

also: dose escalation, dose ramping

The gradual adjustment of a peptide dose — typically starting low and stepping up — to minimize side effects while establishing effective exposure.

also: GLP-1 receptor agonist, GLP-1RA

A class of peptides that activates the GLP-1 receptor, researched for effects on glucose regulation, gastric motility, and appetite signaling.

also: repair peptide, tissue repair peptide

A class of peptides researched primarily for effects on tissue repair, wound healing, inflammation resolution, and recovery from musculoskeletal injury.

also: anti-aging peptide, healthspan peptide

A class of peptides researched for effects on cellular aging markers, mitochondrial function, telomere maintenance, and healthspan extension.

also: cognitive peptide, brain peptide

A class of peptides researched primarily for effects on cognition, memory, focus, and neurological function.

also: oligopeptide, short peptide

A short chain of amino acids linked by peptide bonds, typically fewer than 50 residues, functioning as a signaling molecule in biological systems.

also: long peptide, oligopeptide chain

A longer chain of amino acids (typically 50+ residues) that may or may not fold into a functional protein structure.